News

Oncovita raise 8M€ to support the development of its MVdeltaC immunotherapeutic vaccine in oncology

MVdeltaC: a new therapeutic vaccine derived from measles vaccine with promising preclinical immuno-oncolytic activities (Abstract)

Three-in-one Vaccine: A Single Recombinant Measles Virus Expressing Three Arbovirus Antigens Induces Robust Humoral and Cell-Mediated Immune Responses, Conferring Effective Protection in a Mouse Model (Abstract)

Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022, Nov 8. (Engl / Fr)

Oncovita presents data of MVdeltaC at Société Française d’Immunothérapie du Cancer (FITC), Institut Curie, Paris, 11 octobre 2022